未登录

S

Sarah G. Samaranayake

national institutes of health (nih) - usa

H指数:8

被引数:261

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Germline CDH1 Variants and Lifetime Cancer Risk

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

IF55

2024-09-033

PRE

Knockout on enhancer of zeste homolog 2 in triple-negative breast cancer model alters immune signaling and decreases tumor progression and lung metastasis

CANCER RESEARCH

IF16.6

2024-03-220

PRE

Defining features of hereditary lobular breast cancer due to CDH1 with magnetic resonance imaging and tumor characteristics ( vol 9 , 77 , 2023)

NPJ BREAST CANCER

IF7.6

2023-10-230

OAAI

Defining features of hereditary lobular breast cancer due to CDH1 with magnetic resonance imaging and tumor characteristics

NPJ BREAST CANCER

IF7.6

2023-09-273

OAAI

Early Immune Changes Support Signet Ring Cell Dormancy in CDH1-Driven Hereditary Diffuse Gastric Carcinogenesis

MOLECULAR CANCER RESEARCH

IF4.7

2023-09-143

OA

Micronutrient Supplementation and Bone Health After Prophylactic Total Gastrectomy in Patients With CDH1 Variants

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

IF5.1

2023-03-235

OA

Soluble E-Cadherin as a Potential Biomarker in Hereditary Diffuse Gastric Cancer Syndrome

ANNALS OF SURGICAL ONCOLOGY

IF3.5

2022-07-260

PRE

Decision-making and regret in patients with germline CDH1 variants undergoing prophylactic total gastrectomy

JOURNAL OF MEDICAL GENETICS

IF3.7

2022-07-118

OA

Surveillance breast magnetic resonance findings in asymptomatic CDH1 variant carriers

CANCER RESEARCH

IF16.6

2022-02-150

PRE

Metformin reduces PD-L1 on tumor cells and enhances the anti-tumor immune response generated by vaccine immunotherapy

二甲双胍降低肿瘤细胞PD-L1并增强疫苗免疫治疗产生的抗肿瘤免疫反应

JOURNAL FOR IMMUNOTHERAPY OF CANCER

IF10.6

2021-11-2344

OAAI